6 March 2024

Revisit the latest webinar from the MEPs Against Cancer (MAC) Interest Group, which explored how the ongoing reform of the EU pharmaceutical framework is an opportunity to make the pharmaceutical system patient-centred and fit for purpose. 

Speakers addressed the importance of addressing unmet medical needs and ensuring availability and timely access to safe, effective, and affordable medicines for all patients in need. 

As the longest-standing group of MEPs dedicated to addressing the entire cancer continuum – from prevention and treatment to survivorship – the MEPs Against Cancer group brings together policymakers from across the political spectrum and EU member states to promote ambitious EU action against cancer. The group is supported by the Association of European Cancer Leagues (ECL), which unites 33 national and regional cancer leagues across Europe.